Developer docs
API playgroundTry for free, no card

Search company profiles

Molecular Templates

Full company profile

uuid0004o2w

Namestring
Molecular Templates
Legal namestring
Molecular Templates, Inc.
Websiteurl
mtem.com
Company typeenum
Public
Founded yearint
2006
Descriptiontext

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases, with operations historically based in Austin, Texas and a public listing on Nasdaq under the ticker MTEM. The company's focus was oncology, addressing treatment needs for oncology patients through proprietary technology platforms for targeted cancer therapeutics; its customer segment was effectively the oncology/hospital use case, though the company never commercialized any approved products and derived no product revenue. The business model relied entirely on external capital — successive private placements and PIPE financings from healthcare-dedicated investors (notably BVF Partners L.P., BB Biotech AG, Santé, Longitude Capital, Perceptive Advisors, Takeda, and Frazier Healthcare Partners) — to fund ongoing clinical studies, working capital, and general corporate purposes.

Over its operating life Molecular Templates raised cumulative equity financing of approximately $400 million across more than a dozen rounds from 2009 through 2024, executed one acquisition (Threshold Pharmaceuticals in 2017), and assembled a small executive team including a CEO/CSO, CMO, and President/COO. Despite this funding history, the company failed to bring a product to market, and by 2024 was trading at distressed levels on Nasdaq while facing delisting risk, implementing staff cuts, and pursuing strategic alternatives. The company subsequently ceased operations, with its current website explicitly stating that Molecular Templates is no longer operating and routing any inquiries to a third-party contact email in Foxboro, Massachusetts.

Short descriptiontext

Molecular Templates was a clinical-stage biopharmaceutical company developing engineered therapeutic compounds for oncology; headquartered in Austin, TX, it was publicly traded on Nasdaq (MTEM) but never commercialized an approved product and has ceased operations.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics, biopharmaceutical development, clinical-stage drugs, targeted cancer therapy, cancer drug development
Industry3 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Oncology Biopharmaceuticals
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Molecular Templates was a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. The company had no approved products and was pursuing strategic alternatives prior to ceasing operations in 2024. Its activities centered on proprietary technology platforms intended to generate targeted oncology therapeutics.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company focused on oncology. The company is no longer operating (as stated on their website). No active products, services, or product portfolio information is available in the source data.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biotech developing engineered protein-based immunotherapies; comparable in development stage, modality (engineered biologic), and oncology focus to MTEM's platform.

TypeDirect peer
Description

Clinical-stage biotech engineering masked, targeted protein therapeutics for oncology; highly comparable platform-approach to MTEM's engineered toxin body strategy.

TypeDirect peer
Description

Clinical-stage oncology company developing engineered antibody-drug conjugates and protein therapeutics; similar stage, modality, and oncology indication focus.

TypeDirect peer
Description

Biotech specializing in engineered antibody and protein therapeutics for oncology and serious diseases; comparable modality and therapeutic focus as MTEM.

5Heat Biologics
TypeDirect peer
Description

Clinical-stage oncology biotech developing protein-based immunotherapies; similar development stage and oncology focus as MTEM.

TypeBroad incumbent
Description

Established biotech developing engineered antibody-based cancer therapeutics; comparable oncology biologics platform at commercial scale (now part of AbbVie).

TypeBroad incumbent
Description

Large biotechnology company with a broad portfolio of engineered protein therapeutics in oncology; overlaps with MTEM's modality at significantly larger scale.

TypeBroad incumbent
Description

Major oncology biologics developer with deep portfolio of engineered antibody and protein therapeutics; broadly comparable as a leading player in MTEM's target space.

TypeEmerging player
Description

Protein engineering company applying directed evolution to therapeutic enzymes and proteins; overlapping platform technology with MTEM's protein engineering approach.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Major pharmaceutical company with significant oncology biologics franchise; comparable end-market and therapeutic protein modality, though vastly larger and more diversified.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Molecular Templates

Clinical-Stage Oncology Biopharmaceuticalsmtem.com

Molecular Templates was a clinical-stage biopharmaceutical company developing engineered therapeutic compounds for oncology; headquartered in Austin, TX, it was publicly traded on Nasdaq (MTEM) but never commercialized an approved product and has ceased operations.

What Molecular Templates does

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases, with operations historically based in Austin, Texas and a public listing on Nasdaq under the ticker MTEM. The company's focus was oncology, addressing treatment needs for oncology patients through proprietary technology platforms for targeted cancer therapeutics; its customer segment was effectively the oncology/hospital use case, though the company never commercialized any approved products and derived no product revenue. The business model relied entirely on external capital — successive private placements and PIPE financings from healthcare-dedicated investors (notably BVF Partners L.P., BB Biotech AG, Santé, Longitude Capital, Perceptive Advisors, Takeda, and Frazier Healthcare Partners) — to fund ongoing clinical studies, working capital, and general corporate purposes.

Over its operating life Molecular Templates raised cumulative equity financing of approximately $400 million across more than a dozen rounds from 2009 through 2024, executed one acquisition (Threshold Pharmaceuticals in 2017), and assembled a small executive team including a CEO/CSO, CMO, and President/COO. Despite this funding history, the company failed to bring a product to market, and by 2024 was trading at distressed levels on Nasdaq while facing delisting risk, implementing staff cuts, and pursuing strategic alternatives. The company subsequently ceased operations, with its current website explicitly stating that Molecular Templates is no longer operating and routing any inquiries to a third-party contact email in Foxboro, Massachusetts.

Molecular Templates firmographics

Firmographics
Name
Molecular Templates
Legal name
Molecular Templates, Inc.
Website
https://mtem.com
Company type
Public
Founded year
2006
Operating status
Closed
Headcount range
11–50 employees
Short description
Molecular Templates was a clinical-stage biopharmaceutical company developing engineered therapeutic compounds for oncology; headquartered in Austin, TX, it was publicly traded on Nasdaq (MTEM) but never commercialized an approved product and has ceased operations.
Ownership category
akta.pro rank

Molecular Templates industry classification

Industry
Product category
Clinical-Stage Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology therapeutics
  • Biopharmaceutical development
  • Clinical-stage drugs
  • Targeted cancer therapy
  • Cancer drug development

Where Molecular Templates is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Molecular Templates business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Molecular Templates product offering

Product offering

Core offering

Molecular Templates was a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. The company had no approved products and was pursuing strategic alternatives prior to ceasing operations in 2024. Its activities centered on proprietary technology platforms intended to generate targeted oncology therapeutics.

Product overview

Molecular Templates, Inc. was a clinical-stage biopharmaceutical company focused on oncology. The company is no longer operating (as stated on their website). No active products, services, or product portfolio information is available in the source data.

Differentiator

Problem solved

Functional benefit

Companies that use Molecular Templates

Customer profile

Segments1 record

Ideal customer profiles2 records

Molecular Templates technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Molecular Templates partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights2 records

Molecular Templates competitors and assessment

Company assessment

Direct peers

  • Bolt Biotherapeutics: Clinical-stage oncology biotech developing engineered protein-based immunotherapies; comparable in development stage, modality (engineered biologic), and oncology focus to MTEM's platform.
  • CytomX Therapeutics: Clinical-stage biotech engineering masked, targeted protein therapeutics for oncology; highly comparable platform-approach to MTEM's engineered toxin body strategy.
  • Mersana Therapeutics: Clinical-stage oncology company developing engineered antibody-drug conjugates and protein therapeutics; similar stage, modality, and oncology indication focus.
  • Genmab: Biotech specializing in engineered antibody and protein therapeutics for oncology and serious diseases; comparable modality and therapeutic focus as MTEM.
  • Heat Biologics: Clinical-stage oncology biotech developing protein-based immunotherapies; similar development stage and oncology focus as MTEM.

Broad incumbents

  • ImmunoGen (AbbVie): Established biotech developing engineered antibody-based cancer therapeutics; comparable oncology biologics platform at commercial scale (now part of AbbVie).
  • Amgen: Large biotechnology company with a broad portfolio of engineered protein therapeutics in oncology; overlaps with MTEM's modality at significantly larger scale.
  • Genentech (Roche): Major oncology biologics developer with deep portfolio of engineered antibody and protein therapeutics; broadly comparable as a leading player in MTEM's target space.
  • Bristol-Myers Squibb: Major pharmaceutical company with significant oncology biologics franchise; comparable end-market and therapeutic protein modality, though vastly larger and more diversified.

Emerging players

  • Codexis: Protein engineering company applying directed evolution to therapeutic enzymes and proteins; overlapping platform technology with MTEM's protein engineering approach.

Market position

Strengths1 record

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Molecular Templates social profiles

Digital presence

Molecular Templates financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Molecular Templates leadership team

Management profile

Number of profiles

Molecular Templates funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Molecular Templates M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molecular Templates

What does Molecular Templates do?

Molecular Templates was a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. The company had no approved products and was pursuing strategic alternatives prior to ceasing operations in 2024. Its activities centered on proprietary technology platforms intended to generate targeted oncology therapeutics.

Is Molecular Templates a public or private company?

Molecular Templates is a public company. It is classified as public and is currently closed.

When was Molecular Templates founded?

Molecular Templates was founded in 2006. It employs 11 to 50 people.

Where is Molecular Templates based?

Molecular Templates is headquartered in Austin, United States, in the North America region.

Who are Molecular Templates's main competitors?

Direct peers on record are Bolt Biotherapeutics, CytomX Therapeutics, Mersana Therapeutics, Genmab and Heat Biologics. Broad incumbents are ImmunoGen (AbbVie), Amgen, Genentech (Roche) and Bristol-Myers Squibb. Codexis is listed as an emerging player.

Does Molecular Templates have an API?

No public API is recorded for Molecular Templates.

What industry is Molecular Templates in?

Molecular Templates's product category is Clinical-Stage Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AD HOC NEWSMolecular Templates stock (US60877T1007): restructuring moves keep delisting?risk biotech in focusMolecular Templates (ticker MTEM), a clinical-stage oncology-focused biotech company, is pursuing strategic alternatives after facing Nasdaq delisting risk and implementing staff cuts amid balance sheet stress, with the stock trading at distressed levels. The company, which has no approved products and depends heavily on external capital raises and potential pharmaceutical partnerships to fund operations, operates in a highly competitive oncology landscape where broader market conditions for pre-revenue biotech stocks have been unfavorable. The combination of company-specific challenges—including delisting risk, restructuring, and limited cash runway—alongside sector-wide pressures illustrates the elevated financing and execution risks facing small-cap biotech investors.BenzingaWhy Molecular Templates (MTEM) Stock Is Down 60%Molecular Templates Inc (NASDAQ:MTEM) shares dropped 60% to 13 cents after the company announced it received a Nasdaq delisting notice, citing its classification as a "public shell," failure to file Q3 2024 quarterly reports, and failure to maintain the minimum $1.00 bid price. Trading of the company's common stock is set to be suspended on December 26, with the delisting to be formalized with the SEC following the suspension. Molecular Templates has stated it does not intend to appeal Nasdaq's decision.BenzingaWhy Molecular Templates (MTEM) Stock Is Down 77% TodayMolecular Templates Inc announced on October 11 that its board approved a plan to liquidate and wind up the company due to lack of viable strategic alternatives, pending stockholder approval. Shares plummeted 77% to $0.35 during trading, with the company noting it does not expect shareholders to receive any value upon dissolution. The company will reduce its workforce, wind down Phase 1 clinical trials, and continue FDA discussions for drug MT-0169 while retaining only key management for the wind-up process.GlobeNewswireMolecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate UpdateMolecular Templates reported Q2 2024 net loss of $8.1M and revenue of $0.6M, down from $10.9M loss and $6.9M revenue in 2023. Cash of $9.7M supports operations into Q4 2024. The company highlighted ongoing clinical activity for its ETB programs.GlobeNewswireMolecular Templates, Inc. Provides Interim UpdateMolecular Templates provided an interim update on its clinical-stage programs, highlighting monotherapy activity of MT-6402 in checkpoint-experienced solid tumor patients, including partial responses in head and neck cancer and an unconfirmed response in lung cancer. The company also reported early clinical data on MT-0169 for CD38+ cell depletion in immune-mediated diseases.GlobeNewswireMolecular Templates, Inc. Reports First Quarter 2024Molecular Templates reported Q1 2024 net income of $0.6 million and revenue of $11.1 million, down from $10.8 million and $36.6 million in 2023. The company completed a second financing closing with $9.5 million in proceeds, and expects cash to support operations into Q4 2024.BenzingaWhat's Going On With Molecular Templates Stock?Molecular Templates presented interim Phase I data for MT-6402 in patients with PD-L1+ solid tumors, reporting that the drug was well-tolerated with no Grade 4 or 5 adverse events and showed objective responses in heavily pre-treated head and neck cancer patients with low PD-L1 expression. The company's shares moved on heavy trading volume Tuesday, with over 1.47 million shares traded compared to the 100-day average of less than 27,000 shares, though the stock was down 4.1% at $1.90 at publication.GlobeNewswireMolecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business UpdateMolecular Templates reported Q4 2023 net loss of $3.9 million and revenue of $7.0 million, with cash runway extending to Q4 2024 after a $9.5 million private placement. The company also announced termination of its Bristol-Myers Squibb collaboration agreement.BioSpaceMolecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase AgreementMolecular Templates, Inc. announced a definitive agreement to close the second tranche of its private placement, securing $9.5 million in gross proceeds from existing and new healthcare investors. The financing, led by BVF Partners L.P., involves the issuance of common stock and warrants at $2.60 per share, with Stifel acting as the sole placement agent. Molecular Templates intends to utilize the net proceeds to fund ongoing clinical studies, working capital, and general corporate purposes.GlobeNewswireMolecular Templates, Inc. Provides Interim UpdateMolecular Templates provided an interim update on its ETB programs, reporting monotherapy activity with MT-6402 in heavily pre-treated head and neck cancer patients, including partial responses. The first dose of MT-8421 was cleared with no grade 3 or 4 toxicities, and enrollment in the second cohort is ongoing. The company also plans to initiate a study of MT-0169 in CD38+ AML with MD Anderson.